GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tharimmune Inc.
The shares of Tharimmune, a biotech company, reflect the potential of its drug candidates. The price trajectory is highly speculative and depends on the results of preclinical and early clinical trials, which investors are pinning high hopes on.
Share prices of companies in the market segment - Cancer cure
Tharimmune is a biopharmaceutical company developing drugs to treat rare liver diseases and oncology. We categorize it as a "Cancer Treatment" company. The chart below shows how investors value companies with a diversified portfolio across multiple therapeutic areas.
Broad Market Index - GURU.Markets
Tharimmune is an oncology company developing drugs to treat cancer and immune diseases. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock price to assess the outlook for this industry.
Change in the price of a company, segment, and market as a whole per day
THAR - Daily change in the company's share price Tharimmune Inc.
Tharimmune, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its liver disease and cancer treatments.
Daily change in the price of a set of shares in a market segment - Cancer cure
Tharimmune, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with THAR's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Tharimmune is a biotech company developing drugs to treat cancer. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tharimmune Inc.
Tharimmune, Inc.'s year-over-year performance is a story of developing drugs for rare liver diseases and oncology. Its 12-month market cap is entirely dependent on progress in preclinical and clinical trials. Every successful step confirms the potential of its scientific platform and brings the development of new drugs closer.
Annual dynamics of market capitalization of the market segment - Cancer cure
As an early-stage biotech, Tharimmune is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tharimmune is a biotech company whose value is tied to the hope of developing a new cancer drug. Its year-over-year performance relative to the market isn't a reflection of business processes, but a speculative bet on laboratory success. Its chart is a series of sharp movements driven by news about clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tharimmune Inc.
Tharimmune is a biopharmaceutical company. Its monthly performance is typical for the sector: it depends entirely on progress in its scientific developments and clinical programs. News of trial results or funding are the main drivers.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Tharimmune is a biotech company developing drugs for the treatment of oncology and immune diseases, using its proprietary platform to improve drug delivery. The graph below illustrates the overall dynamics in the oncology sector, where innovative delivery methods can improve efficacy and reduce side effects.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tharimmune is a clinical-stage biotech focused on cancer treatment. Its shares exist in a world of their own, driven by research results and regulatory announcements. The company's performance is completely unrelated to overall market trends, representing a pure bet on scientific success.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tharimmune Inc.
Tharimmune is a clinical-stage biopharmaceutical company. Its weekly stock price performance reflects speculative bets on the success of its candidates for liver disease and cancer treatments. Lab and clinical news are the main drivers of the stock price.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Tharimmune is a biotech startup focused on cancer treatment, which carries high risks and potential. This chart shows how the company's shares react to research news compared to the sector. Is the company's volatility a personal story or part of a broader industry trend?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Tharimmune is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
THAR - Market capitalization of the company Tharimmune Inc.
The Tharimmune, Inc. chart is a speculative curve of hopes in biotech. Its market cap reflects not current revenues, but investors' faith in the potential of its developments to treat rare liver diseases and cancer. It's a highly volatile story, typical of early-stage companies.
THAR - Share of the company's market capitalization Tharimmune Inc. within the market segment - Cancer cure
Tharimmune is a biopharmaceutical company focused on the treatment of cancer and inflammatory diseases. In the oncology segment, its market capitalization reflects the potential of its scientific developments. The dynamics of this metric are a sensitive barometer of news on the progress of clinical trials, which determine the company's future.
Market capitalization of the market segment - Cancer cure
Tharimmune develops drugs to treat cancer. How big is this arena? The chart below shows the pulse of the entire cancer treatment sector. Its high volatility reflects both the enormous hopes for new breakthrough drugs and the high risks associated with their development and clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Tharimmune chart shows how the market values an early-stage biotech company focused on treating liver diseases and oncology. Its extremely low market cap is a pure venture option on the success of its research. This diagram illustrates the binary risk: breakthrough or nothing.
Book value capitalization of the company, segment and market as a whole
THAR - Book value capitalization of the company Tharimmune Inc.
For Tharimmune, Inc., a biopharmaceutical company, book value is its tangible assets, consisting of R&D assets, drug rights, and financial reserves for clinical trials. The chart below shows how this scientific and financial capital was formed and changed.
THAR - Share of the company's book capitalization Tharimmune Inc. within the market segment - Cancer cure
Tharimmune, Inc. is a biopharmaceutical company whose tangible assets are research laboratories focused on the treatment of liver diseases and oncology. The chart shows the share of this specialized R&D infrastructure in its therapeutic niche controlled by this innovative company.
Market segment balance sheet capitalization - Cancer cure
Tharimmune is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Tharimmune focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Tharimmune's assets are not factories, but a scientific platform and capital dedicated to developing immunotherapies for cancer and liver disease. Its book value reflects its financial and laboratory resources for conducting research in these complex areas of medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tharimmune Inc.
Tharimmune is a biotech company focused on treating liver diseases and oncology. Its market capitalization is a bet on its scientific developments. The chart shows the volatility typical of early-stage biotechs, whose value depends entirely on future clinical trial results.
Market to book capitalization ratio in a market segment - Cancer cure
Tharimmune develops drugs for the treatment of oncology and immune diseases. Like many biotech companies, its value is determined by expectations for clinical trials. The chart shows a high market valuation of its scientific potential relative to its tangible assets.
Market to book capitalization ratio for the market as a whole
Tharimmune develops cancer drugs. The company's value is determined solely by its intellectual property and the potential of the molecules it studies. This chart illustrates how investor expectations in the biotech sector influence valuations, creating a huge gap between market value and book value.
Debts of the company, segment and market as a whole
THAR - Company debts Tharimmune Inc.
Tharimmune is a biopharmaceutical company focused on the treatment of oncology and immune diseases. Being in the early stages of development, the company incurs significant expenditures on research and preclinical trials. This chart shows how the company manages its capital, raising funds to advance its scientific hypotheses to the clinical trial stage.
Market segment debts - Cancer cure
Tharimmune is a clinical-stage oncology company. Its financial model is typical of biotech: no sales revenue and complete reliance on equity capital to fund lengthy and expensive clinical trials. This chart is an indicator of its financial health, showing the "headroom" for continued development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tharimmune Inc.
Tharimmune is a biopharmaceutical company focused on cancer treatment. This chart shows its reliance on external financing. As with most development-stage biotechs, any debt is a significant risk factor, as the company lacks stable cash flow to service it, and everything depends on the success of future trials.
Market segment debt to market segment book capitalization - Cancer cure
Tharimmune is a biopharmaceutical company developing treatments for cancer and inflammatory diseases. Clinical trials in these areas require significant investment. The chart shows the overall debt burden in the pharmaceutical industry, providing investors with context for assessing the company's financial strategy on its long journey to potential commercialization.
Debt to book value of all companies in the market
Tharimmune, Inc. is a biopharmaceutical company focused on the treatment of liver diseases and cancer. Being in early development, it has no stable revenue. This chart shows that for such companies, debt financing is not an option, and their survival and growth depend entirely on their ability to attract equity capital.
P/E of the company, segment and market as a whole
P/E - Tharimmune Inc.
For Tharimmune, an oncology company, the P/E ratio is not applicable because it lacks consistent sales revenue. Any values on this chart are random. Investors evaluate the company solely on the potential of its scientific developments and the likelihood of success of future cancer treatments.
P/E of the market segment - Cancer cure
Tharimmune is a clinical-stage biopharmaceutical company developing immunotherapeutic drugs for the treatment of cancer and inflammatory diseases. This chart shows the average valuation for the sector, providing investors with context for assessing Tharimmune's scientific potential and portfolio.
P/E of the market as a whole
Tharimmune is a biopharmaceutical company specializing in the development of drugs for the treatment of oncology and immune diseases. Its valuation is entirely dependent on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tharimmune Inc.
Tharimmune is a biopharmaceutical company developing immuno-oncology drugs. This chart reflects investor expectations for the clinical trials of its candidates for the treatment of cancer and liver diseases. The company's valuation is based on the projected future success of its developments, rather than current revenue, as is typical in the biotech sector.
%20P%2FE%20Tharimmune%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tharimmune-Inc.&v=1772630400796 "Chart of the company's future (projected) P/E Tharimmune Inc.")
Future (projected) P/E of the market segment - Cancer cure
Tharimmune is a biotech company focused on developing treatments for oncology and immune diseases. Its valuation relative to other biotechs reflects investor opinions on the potential of its scientific platform. This demonstrates the market's confidence in its ability to successfully advance its developments through clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772630400853 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Tharimmune is a biopharmaceutical company, likely in the early stages, focused on cancer treatment. Its valuation is a bet on the success of its scientific platform and clinical candidates. This chart reflects the overall risk appetite of investors, which is a key factor in funding long-term and capital-intensive oncology research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772630400898 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tharimmune Inc.
Tharimmune is a biopharmaceutical company developing immunotherapeutic drugs for the treatment of cancer and inflammatory liver diseases. The financial indicators reflected in the chart primarily represent research expenses. The company's success depends on advancing its candidates through clinical trials.
Profit of companies in the market segment - Cancer cure
Tharimmune, Inc. is a biopharmaceutical company focused on developing treatments for oncology and immunology diseases. This chart is a health indicator for the entire biotech sector. It shows the willingness of investors and large pharmaceutical companies to fund early-stage development, which is critical for such companies.
Overall market profit
Tharimmune is a biotech company specializing in cancer treatment. Like most early-stage companies in this sector, its prospects are unrelated to the overall economic outlook. THAR's success depends on scientific discoveries, clinical trial results, and regulatory approvals, not on the corporate earnings cycles depicted in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tharimmune Inc.
Tharimmune is a biotech company developing drugs to treat oncology and immune diseases. Its future profit forecast depends on progress in clinical trials and potential partnerships with major pharmaceutical companies. This chart shows how analysts assess the scientific merit of its developments and their commercial prospects.
%20profit%20of%20the%20company%20Tharimmune%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tharimmune-Inc.&v=1772630401495 "Graph of future (projected) profit of the company Tharimmune Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Tharimmune is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of oncology and immunology diseases. The company's future depends entirely on the success of its research. This chart shows forecasts for the cancer treatment sector. It provides context for understanding the enormous potential the industry holds should new therapies be successful.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772630401555 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
For the research-stage biopharmaceutical company Tharimmune, this schedule is important from an investment climate perspective. Expectations of economic growth increase investors' risk appetite and facilitate raising funds for the development of new cancer treatments, while a recession complicates this process.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772630401612 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tharimmune Inc.
Tharimmune is an early-stage biotech company. This metric, despite its minimal revenue, is a clear indicator of investors' faith in its scientific approach. It's not an assessment of its business, but rather of the potential of its developments to treat complex diseases.
P/S market segment - Cancer cure
Tharimmune is a biopharmaceutical company developing immuno-oncology drugs for the treatment of cancer. This chart shows the average valuation in the oncology sector. It reflects investor expectations for the potential of Tharimmune's developments and the risks associated with lengthy and expensive clinical trials in this highly competitive field.
P/S of the market as a whole
Tharimmune, Inc. is a biopharmaceutical company focused on developing drugs to treat oncology and immune diseases. The company is in early development, and its valuation is based on the potential of its technologies. This chart clearly illustrates the difference between the valuation of future expectations and the market's assessment of current revenues.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tharimmune Inc.
Tharimmune is a biopharmaceutical company developing treatments for oncology and immune diseases. Its valuation depends on the future success of its drugs in clinical trials. This chart shows how investors assess the scientific potential of its developments and the likelihood of their future commercialization.
%20P%2FS%20Tharimmune%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tharimmune-Inc.&v=1772630401891 "The graph of the company's future (projected) P/S Tharimmune Inc.")
Future (projected) P/S of the market segment - Cancer cure
Tharimmune is a biotech company developing immunotherapies for the treatment of oncology and inflammatory diseases, with a particular focus on liver disease. Its technology utilizes a unique drug delivery mechanism. This chart shows how the market views the potential of its scientific platform compared to other pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772630402073 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
This chart shows investor appetite for pharmaceutical innovation. For Tharimmune, a company developing drugs to treat rare oncological and immunological diseases, this is an indicator of capital availability. Market optimism creates a favorable environment for funding research into niche, yet highly important, drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772630402395 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tharimmune Inc.
Tharimmune is a biopharmaceutical company developing immunomodulators for the treatment of oncological and inflammatory diseases. This chart reflects revenue from partnerships and licensing. In the future, it will show revenue from sales of drugs aimed at activating the immune system to fight cancer and chronic inflammation.
Sales of companies in the market segment - Cancer cure
Tharimmune is a biopharmaceutical company developing drugs to treat oncology and immunology diseases. This chart shows financial activity in the cancer drug development sector. Tharimmune uses its platform to improve drug delivery, a key part of its overall efforts to create more effective and safer therapies.
Overall market sales
Tharimmune, Inc. is a biopharmaceutical company developing drugs for the treatment of oncology and immune diseases. Its development is financed by investor capital, the inflow of which depends on the overall state of financial markets. This economic activity schedule indirectly influences investor appetite for risky biotech startups.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tharimmune Inc.
Tharimmune is a biopharmaceutical company developing immuno-oncology drugs for the treatment of cancer and immune-related diseases. Its approach is based on modulating the immune system to combat disease. Future revenue is dependent on the success of clinical trials. This chart reflects analysts' assessment of the scientific potential and commercial prospects of the company's developments.
%20sales%20of%20the%20company%20Tharimmune%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tharimmune-Inc.&v=1772630402643 "Schedule of future (projected) sales of the company Tharimmune Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Tharimmune is a biopharmaceutical company focused on developing treatments for oncology and immune diseases. This chart reflects expectations for the entire oncology sector. It provides insight into the overall market growth potential and the investment climate for the development of new anti-cancer drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772630402672 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Tharimmune, Inc. is a biopharmaceutical company focused on developing drugs for the treatment of oncology and immunology diseases. Its prospects depend on the success of clinical trials. The overall economic situation, reflected in this chart, influences the amount of venture capital funding available to early-stage biotech companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772630402827 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tharimmune Inc.
Tharimmune is a biopharmaceutical company focused on developing new cancer treatments. This chart reflects its financial performance in early-stage research. Negative values represent investments in preclinical and early clinical programs, the success of which determines the company's entire future value and profitability.
Market segment marginality - Cancer cure
Tharimmune is a biopharmaceutical company focused on treating cancer and immune diseases. For a research-stage company, this chart serves as an indicator of potential. It demonstrates the average profitability achieved in its sector and helps estimate the financial results Tharimmune could achieve if its drugs are successful.
Market marginality as a whole
Tharimmune is a biopharmaceutical company focused on developing drugs for the treatment of oncology and immune diseases. This overall economic profitability curve is not a determining factor for the company. Its future value depends on success in clinical trials and the ability to bring innovative drugs to market, not on current market conditions.
Employees in the company, segment and market as a whole
Number of employees in the company Tharimmune Inc.
Tharimmune is a biopharmaceutical company developing new treatments for cancer and immune diseases. This graph shows a small team of scientists and clinicians. This headcount is typical for a company in preclinical and early clinical development, focused on science.
Share of the company's employees Tharimmune Inc. within the market segment - Cancer cure
Tharimmune, Inc. is focused on developing innovative cancer treatments. In this highly competitive biotech field, the scientific team is crucial. This metric reflects the percentage of leading oncologists, biologists, and immunotherapy specialists a company attracts, demonstrating its concentration of intellectual capital in the fight against cancer.
Number of employees in the market segment - Cancer cure
Tharimmune is a biopharmaceutical company developing drugs for the treatment of chronic liver diseases and cancer. The use of nanotechnology for drug delivery is a key feature. This graph illustrates how the intersection of biotechnology and nanomedicine is giving rise to new approaches that require scientists to utilize interdisciplinary expertise to create breakthrough therapies.
Number of employees in the market as a whole
Tharimmune, Inc. is another example of a highly specialized biotech company focused on cancer treatment. This chart shows the macro-level employment, which consists of thousands of such innovative firms. Each of their launches and subsequent staff expansions is a small stream that feeds into the full-flowing river of economic growth.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tharimmune Inc. (THAR)
Tharimmune is a biotech company developing treatments for cancer and rare diseases. This chart represents a pure intellectual capital valuation. The company's value is based on market expectations for its drug candidates and unique delivery platform. The chart shows the high future value the market attributes to these developments, per scientist.
%20of%20the%20company%20Tharimmune%20Inc.%20(THAR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tharimmune-Inc.-THAR&v=1772630403554 "Chart of market capitalization per employee (in thousands of dollars) of the company Tharimmune Inc. (THAR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Tharimmune is a biotech company focused on developing cancer treatments. Like other R&D companies, its value is determined by the potential of its scientific developments. This chart shows how much investors are betting on the Tharimmune team. Comparison with industry benchmarks helps assess whether their approach is considered more or less promising than that of other oncology players.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772630403622 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Tharimmune, Inc. is a biopharmaceutical company developing immuno-oncology drugs. This chart shows the average market value of each employee's contribution, illustrating how the market evaluates the potential of scientific developments to fight cancer.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772630403629 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tharimmune Inc. (THAR)
Tharimmune is a biotech company. Like most clinical-stage R&D firms, it has no commercial products. This graph will likely show a net loss per employee. It reflects how much the company invests in its research staff to develop new drugs.
%20Chart%20Tharimmune%20Inc.%20(THAR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tharimmune-Inc.-THAR&v=1772630403686 "Company Profit Per Employee (in thousands of dollars) Chart Tharimmune Inc. (THAR)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Tharimmune is a biotech company specializing in the development of treatments for cancer and inflammatory diseases. Its business is built on scientific research and intellectual property. This chart shows how the potential of its developments and the effectiveness of its small but highly qualified team of scientists translates into the company's financial value per employee.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772630403974 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Tharimmune (THAR) is a clinical-stage biotech company developing therapies for cancer and rare immune diseases using its IP in drug delivery. It's an R&D business. This chart shows the market average dollar return per employee. For THAR (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772630404437 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tharimmune Inc. (THAR)
Tharimmune is a biopharmaceutical company specializing in oncology. For a company in the development stage, this graph is an indicator of future potential. It reflects the team's goal: to transform scientific discoveries into a commercial product capable of generating significant revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tharimmune-Inc.-THAR&v=1772630404567 "Sales chart per company employee Tharimmune Inc. (THAR)")
Sales per employee in the market segment - Cancer cure
Tharimmune is a clinical-stage biotech company focused on treating oncology and inflammatory diseases. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Tharimmune's staff.
Sales per employee for the market as a whole
Tharimmune is a clinical-stage biotech company focused on developing treatments for cancer and inflammatory diseases. The company has no commercial products and, therefore, no revenue from them. This metric is currently irrelevant. The company's entire value lies in its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Tharimmune Inc. (THAR)
Tharimmune is a very early, preclinical stage biotech company developing drugs to treat cancer and rare diseases. It's a highly speculative venture bet. This chart shows the number of investors who believe the company's chances of bringing its product to market are close to zero and that it will run out of money.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tharimmune-Inc.-THAR&v=1772630404668 "Short Shares Chart for the Company Tharimmune Inc. (THAR)")
Shares shorted by market segment - Cancer cure
Tharimmune, Inc. is a biopharmaceutical company developing drugs to treat oncology and immune diseases using its drug delivery platform. This chart reflects the total short position in the biotech sector. High values indicate general investor skepticism about the success of risky clinical trials or funding challenges in this capital-intensive industry.
Shares shorted by the overall market
Tharimmune is an early-stage biotech. This chart illustrates the overall market pessimism. When fear dominates, investors don't buy "lottery tickets." They see a company with no revenue, a long R&D cycle, and a high risk of failure, and they prefer to divest such an asset and convert it into cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tharimmune Inc. (THAR)
This chart for Tharimmune is a clear barometer of biotech speculation. The company has shifted its focus (now oncology and immunology) and is advancing early projects. "Overheating" (above 70) occurs with any news of progress in preclinical research or the start of human trials. The extremely high risk of failure and constant need for cash lead to "oversold" conditions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tharimmune-Inc.-THAR&v=1772630404799 "RSI 14 indicator chart for the company's stock Tharimmune Inc. (THAR)")
RSI 14 Market Segment - Cancer cure
Tharimmune (THAR) is a "biotech" stock, a "hunter" for cancer and *liver*. The "cancer cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is THAR's growth due to its R&D or is *the entire* biotech sector simply overheated?
RSI 14 for the overall market
Tharimmune (THAR) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast THAR (Tharimmune Inc.)
Tharimmune is a biotech company developing drugs for the treatment of liver diseases (LHD) and oncology. This chart shows the average 12-month analyst forecast. For a company at such an early stage, this represents a collective speculative bet on the success of their clinical trials and the scientific potential of their platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-THAR-Tharimmune-Inc.&v=1772630404901 "A chart showing analyst consensus forecasts for the expected stock price. THAR (Tharimmune Inc.)")
The difference between the consensus estimate and the actual stock price THAR (Tharimmune Inc.)
Tharimmune is a clinical-stage biotech company developing drugs for the treatment of oncology and immune diseases. This chart shows the difference between the market valuation and the consensus estimate. For an R&D company, this gap reflects analysts' confidence in their scientific platform and the likelihood of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-THAR-Tharimmune-Inc.&v=1772630404929 "A chart showing the difference between the consensus forecast and the actual stock price. THAR (Tharimmune Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Tharimmune is a clinical-stage biotech company focused on oncology R&D. Like all junior companies, it depends on investor risk appetite. This chart shows the overall analyst sentiment across the cancer treatment sector. It reflects whether experts believe in new breakthroughs or consider the industry overheated.
Analysts' consensus forecast for the overall market share price
Tharimmune is a clinical-stage biotech focused on immuno-oncology. Like many biotechs without revenue, its value is based on expectations. This chart reflects the overall risk appetite in the market. When analysts are bullish (the chart rises), investors are more willing to fund long-term, risky projects, such as Tharimmune's drug development.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tharimmune Inc.
Tharimmune is a clinical-stage biotech company focused on developing drugs for the treatment of oncology and immune diseases. It's an R&D business with binary risk. This chart is a pure indicator of faith in their science. It doesn't reflect current sales (they don't have any), but rather a speculative assessment of their R&D progress, clinical trial data, and their chances of regulatory approval.
AKIMA Market Segment Index - Cancer cure
Tharimmune (THAR) is a biopharmaceutical company developing drugs for the treatment of cancer and rare inflammatory diseases. In biotech, where R&D risks are high, understanding relative position is important. This chart shows the average value of the composite index for this segment. It helps investors compare Tharimmune's scientific potential and risks with average expectations in the drug development sector.
The AKIM Index for the overall market
Tharimmune is a biotech company developing treatments for immunological and inflammatory liver diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative early-stage scientific play compares to overall economic trends.
